# Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

> **NCT03528408** · PHASE2 · UNKNOWN · sponsor: **Suthee Rapisuwon** · enrollment: 52 (actual)

## Conditions studied

- Melanoma
- Ocular Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03528408
- **Lead sponsor:** Suthee Rapisuwon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-26
- **Primary completion:** 2023-05
- **Final completion:** 2023-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03528408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03528408, "Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03528408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*